Other analyses indicated that ARBs users with invasive breast cancer have a reduced risk of recurrence (Chae et al., 2011, 2013; Mc Menamin et al., 2012), although in one study ARBs were not associated with breast cancer recurrence (Sørensen et al., 2012), an apparent discrepancy that may reflect variations in AT1 levels among different breast cancer populations examined. Here, AGTR1 is linked to breast carcinoma.